Table of Contents
What changed
Revenue declined 11.3% to $2,118.0m and statutory EBITDAF fell 14.3% to $460.0m. PBT dropped 30.0% to $177.0m and NPAT fell 30.2% to $127.0m, with the effective tax rate essentially unchanged at 28.2% (FY22: 28.1%), so the earnings decline is an operating rather than a tax-line story. Management's underlying presentation, which strips out an $84m onerous contract provision ($113m EBITDAF impact) tied to a review of estimated available capacity, shows EBITDAF up 5% to $573m and underlying profit of $211m versus $182m — a very different shape to the statutory result.
The balance sheet moved materially. Gross borrowings rose 41.6% to $1,556.0m, cash fell to $140.0m, and net debt of roughly $1,416.0m lifted net debt to EBITDAF to about 3.1x from 1.7x. Total cash capex stepped up to $585.0m (FY22: $75.0m), of which $472.0m was growth capex. The final dividend was held flat at 21 cps.
What matters
- Underlying vs statutory divergence. The $113m EBITDAF charge on the onerous contract is the single biggest driver of the headline decline. On the company's underlying basis EBITDAF grew 5%, so the read on core trading is materially better than the statutory 14.3% fall suggests — but it depends entirely on accepting the adjustment.
- Leverage has stepped up sharply. Net debt to EBITDAF near 3.1x (from 1.7x) is a structural change, driven by a $457m increase in gross borrowings funding the growth capex program. On underlying EBITDAF of $573m the ratio is closer to 2.5x, still a clear weakening.
- Capital allocation is now investment-led. Capex equated to 27.6% of revenue versus 3.1% prior. The dividend (21 cps final) is covered by pre-lease operating free cash flow of $282.0m (58.2% payout), but not by statutory NPAT (128.9% payout), underscoring that distributions are being funded from cash flow while growth spend is debt-funded.
Expectations
No quantified FY24 guidance or stated financial target was supplied in the extract, so forward shape cannot be benchmarked. The HY23 context does confirm a heavily second-half-weighted year: 1H delivered only 27.4% of full-year EBITDAF and a $7m net loss, with the second half contributing an implied $334m of EBITDAF and $134m of NPAT. That shape makes 1H24 print comparisons against a very soft HY23 base, but the release itself does not commit to any forward number. What the release does support is that the step-up in growth capex is now in the run-rate; what it does not support is a view on when the associated assets contribute to earnings.
Quality of result
Operating cash flow was resilient at $395.0m versus $400.0m, and OCF/EBITDAF actually improved to 85.9% from 74.5% — but this sits alongside a clear working capital drag. Trade receivables rose 78.9% to $238.0m (receivable days roughly doubled to 41 from 20) and inventories rose 46.6% to $85.0m, lifting operating working capital by about $132m. Cash conversion at the reported level held up largely because the onerous contract charge is non-cash; underneath that, collections have lengthened materially and should be watched.
The $84m onerous contract provision is a discrete, disclosed, non-cash item rather than a recurring hit, which supports treating the underlying 5% EBITDAF growth as the cleaner operating read. Against that, the $585.0m capex number is genuine cash out the door, and the resulting leverage increase is durable, not timing.
Unresolved
- What is the cash timing profile of the onerous contract unwind, and is a further capacity-review adjustment possible?
- What earnings contribution and commissioning schedule underpin the $472m of growth capex, and what is the peak leverage the company is prepared to run to?
- Why did trade receivables jump $105m — wholesale price timing, specific counterparty exposure, or retail collection deterioration?
- Is the flat 21 cps final dividend sustainable at statutory payout above 100% if underlying earnings do not recover as the adjusted number implies?
This briefing cannot assess valuation, market-price reaction, or the commercial merits of the specific growth projects absorbing the capex, as no share price, NTA, or project-level disclosure was supplied.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $2118m | $2387m | -11.3% ↓ |
| Net profit after tax | $127m | $182m | -30.2% ↓ |
| Net cash inflow from operating activities | $395m | $400m | -1.2% ↓ |
| Final dividend per share | 21.0c | 21.0c | flat |
| EBITDAF | $460m | $537m | -14.3% ↓ |
| Profit before tax | $177m | $253m | -30.0% ↓ |
| Cash and cash equivalents | $140m | $168m | -16.7% ↓ |
| Total assets | $5808m | $5166m | +12.4% ↑ |
Reference: annolyse.ai/briefings/cen-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| PBT growth | -30.0% | — | — |
| Effective tax rate | 28.2% | 28.1% | — |
| OCF / EBITDAF (cash conversion) | 85.9% | 74.5% | stable |
| FCF pre-lease | $282.0m | $325.0m | −$43.0m |
| FCF / NPAT | 221.7% | 178.6% | complementary conversion metric |
| Capex % revenue | 27.6% | 3.1% | — |
| Capex | $585.0m | $75.0m | +$510.0m |
| Free cash flow | $298.0m | $326.0m | −$28.0m |
| Debtor days | 41.0 | 20.3 | +20.7 days |
| Inventory days | 14.7 | 8.9 | +5.8 days |
| Operating working capital | $323.0m | $191.0m | +$132.0m absorbed |
| Trade debtors | $238.0m | $133.0m | +$105.0m |
| Net debt | $1416.0m | $931.0m | +$485.0m |
| Net debt / EBITDAF | 3.08x | 1.73x | Weakening |
| Gross borrowings | $1556.0m | $1099.0m | +$457.0m |
| Payout ratio vs NPAT | 128.9% | — | — |
| Payout ratio vs FCF pre-lease | 58.2% | — | covered |
| ROE (annualised) | 4.5% | 6.4% | Weakening |
| HY23 share of FY23 revenue | 46.9% | — | Other half was 53.1% |
| HY23 share of FY23 EBITDAF | 27.4% | — | Other half was 72.6% |
| HY23 share of FY23 NPAT | -5.5% | — | Other half was 105.5% |
| Profit from continuing operations | $127.0m | $182.0m | −$55.0m |
Reference: annolyse.ai/briefings/cen-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.